2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 405

Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature
Abstract Number: 1887

Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis
Abstract Number: 1287

Anti-mitochondrial Autoantibodies in Idiopathic Inflammatory Myopathies
Abstract Number: 1788

Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome
Abstract Number: 1591

Anti-ovarian Antibodies Are Not Associated with Premature Menopause in SLE Treated with Cyclophophosphamide
Abstract Number: 131

Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population
Abstract Number: 132

Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients
Abstract Number: 2003

Anti-Polygalacturonic Acid Antibody (PGA-Ab) Induced Bone Destruction in Rheumatoid Arthritis by Promoting Osteoclastogenesis via Integrin Beta 5
Abstract Number: 455

Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use
Abstract Number: 2618

Anti-RNPC-3 Antibodies Are Associated with Nuclear Speckled Immunofluorescence Pattern and Enriched in Triple Negative Systemic Sclerosis Patients
Abstract Number: 2103

Anti-TNF Therapy in Patients with HIV Infection
Abstract Number: 2297

Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System
Abstract Number: 133

Anti-β2GPI Domain 1 Antibodies Stratify High Risk of Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Patients with Antiphospholipid Syndrome
Abstract Number: 2128

Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality
Abstract Number: 2824

Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].